UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~December~~January, ~~2025~~2026

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

AsOn ~~previously disclosed, on November~~January 1227, ~~2025~~2026, Kazia Therapeutics Limited (the “Company”) ~~received~~issued a ~~staff determination~~press ~~letter~~release ~~(the~~titled “~~Staff~~Kazia Therapeutics ~~Letter”)~~Reports ~~from~~Encouraging ~~the~~Preliminary ~~Listing~~Clinical ~~Qualifications~~Responses ~~department~~in ~~(the~~Ongoing ~~“Staff”)~~Phase of1b ~~The~~Study ~~Nasdaq~~of ~~Stock~~Paxalisib ~~Market~~in ~~LLC~~Late-Stage ~~(“Nasdaq”)~~Metastatic ~~indicating~~Triple-Negative ~~that~~Breast ~~the~~Cancer”. ~~Company~~A ~~had~~copy ~~not regained compliance with the minimum $35 million Market Value~~ of ~~Listed~~this ~~Securities~~release ~~requirement~~is ~~pursuant~~attached tohereto ~~Nasdaq~~as ~~Listing~~Exhibit ~~Rule 5550(b)(2) (the “MVLS Requirement”) by November 10, 2025~~99.1 ~~Pursuant to the Nasdaq listing rules~~ and ~~the~~is ~~Staff Letter, unless the Company~~incorporated ~~timely~~herein ~~requested~~by ~~a hearing before the Hearings Panel (the “Panel”), the Company’s securities would be subject to suspension/delisting~~reference. ~~The Company timely requested a hearing before the Panel, which was scheduled for January 8, 2026.~~

OnThe ~~December 18, 2025, the~~ Company ~~received~~hereby aincorporates ~~letter~~by ~~from~~reference the ~~Nasdaq~~information ~~Office~~contained ofherein, ~~General~~including ~~Counsel~~Exhibit ~~notifying the Company that it has regained compliance with Listing Rule 5550(b)(~~99.1), except for the ~~alternative~~quotes $2of Dr.5 ~~million~~John ~~minimum~~Friend, ~~stockholders’~~Chief ~~equity~~Executive ~~requirement~~Officer toof the ~~MVLS Requirement~~Company, ~~and~~contained ~~that the Company is~~ in ~~compliance~~Exhibit ~~with all the applicable listing standards~~99. ~~Accordingly~~1, ~~the~~into ~~hearing was considered moot and cancelled, and Nasdaq has determined to continue~~ the ~~listing of the~~ Company’s ~~ADSs~~registration statements on ~~The~~Form ~~Nasdaq~~F-3 ~~Capital Market~~(File No. 333-281937).

~~The~~EXHIBIT ~~Company~~LIST ~~hereby incorporates by reference the information contained herein into the Company’s registration statement on Form F-3 (File No. 333-281937).~~


Exhibit		Description

99.1		Press Release of Kazia Therapeutics Limited dated January 27, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)
/s/ John Friend
Name:		John Friend
Title:		Chief Executive Officer
Date:		December 19, 2025

Kazia Therapeutics Limited (Registrant)

/s/ John Friend

Name: John Friend

Title: Chief Executive Officer

Date: January 27, 2026

Filing Compare · KAZIA THERAPEUTICS LTD